The Infernal Triad: Matrix Gla-Protein (MGP), Vitamin K and Vascular Calcification

As one of the world’s leading nephrologists, Prof. Ziad A. Massy, MD, PhD, FERA (Paris, France) provided new insights into vascular calcification in chronic kidney disease patients. Using the analogy of bone remodelling, he described the relationship between vascular remodelling with abnormal bone and abnormal blood vessel function. Prof. Massy concluded his presentation by stating the retention of uremic toxins contribute to the development of both cardiovascular disease and chronic kidney disease-mineral bone disorder (CKD-MBD)

Dr. Leon Schurgers (Maastricht, the Netherlands), a pioneering researcher on MGP, energetically lead the audience through the ‘Vitamin K-dependent matrix Gla-Protein: a crucial switch to control ectopic mineralisation’ discussion. He provided evidence for the linkage between calcification mechanism, Vitamin K and MGP. He highlighted data showing active dephosphorylated-uncarboxylated isoforms of MGP in serum or plasma that are recognised by the IDS-iSYS InaKtif MGP assay reflects the status of vitamin K. Dr. Schurgers informed the audience that the fully automated IDS-iSYS InaKtif MGP test, from IDS will be available in 2016 for monitoring the vitamin K status in their patients.

Dr. Katarzyna Maresz (Poland) presented data showing that vitamin K2 supplementation slows down calcification progression and surprisingly, reversed the calcification in a few studies. The effect was attributed to carboxylation of MGP thereby enhancing its calcification inhibitory function.

nato-q-7

 

Download Brochure: Chronic Kidney Disease-Mineral
Bone Disorder (CKD-MBD): Overview
(1.5MB)

Download Brochure: Matrix Gla-Protein: Overview (1.5MB)

Disclaimer:The views and opinions expressed by presenters are their own and do not necessarily represent those of IDS.

IDS disclaims any responsibility for the use and application of information presented at this conference.